Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine
Stockholm University, Faculty of Social Sciences, Department of Psychology.
Show others and affiliations
2008 (English)In: Neurobiology of Aging, ISSN 0197-4580, Vol. 29, no 2, 168-184 p.Article in journal (Refereed) Published
Abstract [en]

The relationship between acetylcholinesterase (AChE) activity in the CSF and brain of patients with Alzheimer's disease (AD) was investigated in 18 mild AD patients following galantamine treatment. The first 3 months of the study had a randomized double-blind placebo-controlled design, during which 12 patients received galantamine (16–24 mg/day) and six patients placebo. This was followed by 9 months galantamine treatment in all patients. Activities and protein levels of both the “read-through” AChE (AChE-R) and the synaptic (AChE-S) variants in CSF were assessed in parallel together with the regional brain AChE activity by 11C-PMP and PET. The AChE-S inhibition was 30–36% in CSF, which correlated well with the in vivo AChE inhibition in the brain. No significant AChE inhibition was observed in the placebo group. The increased level of the AChE-R protein was 16% higher than that of AChE-S. Both the AChE inhibition and the increased level of AChE-R protein positively correlated with the patient's performance in cognitive tests associated with visuospatial ability and attention. In conclusion, AChE levels in CSF closely mirror in vivo brain AChE levels prior to and after treatment with the cholinesterase inhibitors. A positive cognitive response seems to dependent on the AChE inhibition level, which is balanced by an increased protein level of the AChE-R variant in the patients.

Place, publisher, year, edition, pages
2008. Vol. 29, no 2, 168-184 p.
Keyword [en]
Alzheimer's disease, acetylcholinesterase, positron emission tomography (PET), cerebrospinal fluid (CSF), red blood cells (RBC), galantamine
National Category
Psychology
Identifiers
URN: urn:nbn:se:su:diva-17388DOI: doi:10.1016/j.neurobiolaging.2006.09.020PubMedID: 17196712OAI: oai:DiVA.org:su-17388DiVA: diva2:183909
Note
This research was sponsored by the Medical Research Council (project no. 05817), Stiftelsen for Gamla Tjänarinnor, KI foundations, Stohne's foundation, and Janssen-Cilag (Sweden and USA).Available from: 2009-01-14 Created: 2009-01-14 Last updated: 2011-01-10Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Almkvist, Ove
By organisation
Department of Psychology
Psychology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 43 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf